MarketPulse
M

$MRNA

26 articles found
13 positive
5 negative
8 neutral
The Motley FoolThe Motley Fool··Adria Cimino

Coatue Management Exits CoreWeave While Establishing Moderna Position

Coatue Management exited CoreWeave with 80% gains, reallocating capital toward a new Moderna position ahead of the biotech stock's 50% rally.
CRWVTSMMRNAportfolio rebalancing13F filings
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology
The Motley FoolThe Motley Fool··Adria Cimino

Market Pullback Presents Entry Points in AI and Life Sciences Leaders

Market volatility creates buying opportunities in AI and biotech leaders Nvidia, Moderna, and Amazon Web Services, each positioned to benefit from industry growth trends.
NVDAAMZNMRNAmarket declinecloud computing
The Motley FoolThe Motley Fool··Emma Newbery

Tech Stocks Drive Market Higher on AI Infrastructure Optimism

Tech stocks surge as S&P 500 gains 0.56% on AI infrastructure optimism. Nvidia leads rally following Meta partnership announcement for data center chips.
NVDAMETAPLTRXLEDINO+2data centersAI infrastructure
BenzingaBenzinga··Vandana Singh

FDA Accepts Moderna Flu Vaccine Application After Prior Rejection

FDA accepts Moderna's flu vaccine application after prior rejection, setting August priority review date. Stock surges 5.77% as company expands mRNA pipeline beyond COVID-19.
MRNAFBTXBIFDA approvalearnings beat
BenzingaBenzinga··Piero Cingari

Market Gains Ground as January Inflation Moderates Below Forecasts

January inflation came in below expectations at 2.4%, hitting eight-month lows. Markets rallied as investors bet on potential Fed rate cuts later this year.
COINRDDTMRNARIVNCOHRinflationFederal Reserve